Gerindra is ready to support and guard the TB vaccine follow -up test after BPOM declared safe

Jakarta -Chairman of the Gerindra Parliament Party faction, Budisatrio Djiwandono, said the Food and Drug Supervisory Agency (BPOM) agency said the TB M72 vaccine was safe to use in the advanced test phase. He said Gerindra supports the implementation of the clinical trial of the M72 TB vaccine that will soon take place in Indonesia. “The issuance of a permit by BPOM is a guarantee to the public that this clinical trial is not a trial and error experiment, but part of the scientific process that is measured and strictly monitored,” Budisatrio said in a written statement on Friday (5/16/2025). In the expressed TB vaccine currently being tested, it is no longer testing security aspects, but effectively. Because pre-clinical tests phases 1 and 2 are well passed. Browse to continue with the content “Pre-Clinical Test and Phase 1-2 is well passed, and now we are in Phase 3, where this vaccine product is security. Now we are talking about effectiveness in a broader population, with layered supervision of BPOM, the Ministry of Health, DPR, World Health Organization (WHO), to academics of national tertiary institutions,” he explained. The TB vaccine M72 itself was developed by the Gates Medical Research Institute, which is part of the Gates Foundation, in collaboration with different global research and research industries. Indonesia is one of the countries that plays an important role in the clinical test of phase 3 to evaluate the effectiveness of this vaccine in a large population. Budisatrio also reminded that Indonesia’s participation in this clinical trial provides important opportunities to strengthen and build the independence of the national pharmaceutical industry. However, the Gerindra Party faction emphasized that the whole process must be guided by transparent and accountable. “It is an opportunity for Indonesia to be involved in the research process, technology transfer, to strengthen the production capacity of domestic vaccines. So that it is not just a market, but also a producer who provides solutions to global health problems,” he said. “We in the DPR, especially by Commission IX, will ensure that all phases of clinical trials, both in terms of administration and scientific rules, must be met according to appropriate standards and executed with the highest ethical standards,” he added. Budisatrio invites the public to remain optimistic in welcoming the clinical trial of this TB vaccine. ‘Do not allow fear that it is not based on scientific studies, the opportunity for Indonesia to be free from the threat of TB. This disease is a cause of death in Indonesia that caused 136 thousand deaths each year.